ImmunoCellular Therapeutics Ltd
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company's lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokin… Read more
ImmunoCellular Therapeutics Ltd (IMUC) - Total Assets
Latest total assets as of December 2022: $768.80K USD
Based on the latest financial reports, ImmunoCellular Therapeutics Ltd (IMUC) holds total assets worth $768.80K USD as of December 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ImmunoCellular Therapeutics Ltd - Total Assets Trend (2005–2024)
This chart illustrates how ImmunoCellular Therapeutics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ImmunoCellular Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
ImmunoCellular Therapeutics Ltd's total assets of $768.80K consist of 88.9% current assets and 11.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how ImmunoCellular Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ImmunoCellular Therapeutics Ltd's current assets represent 88.9% of total assets in 2024, a decrease from 97.0% in 2005.
- Cash Position: Cash and equivalents constituted 25.3% of total assets in 2024, up from 2.2% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
ImmunoCellular Therapeutics Ltd Competitors by Total Assets
Key competitors of ImmunoCellular Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
ImmunoCellular Therapeutics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ImmunoCellular Therapeutics Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ImmunoCellular Therapeutics Ltd is currently not profitable relative to its asset base.
ImmunoCellular Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.21 | 3.58 | 2.97 |
| Quick Ratio | 0.21 | 3.58 | 2.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.90 Million | $ 1.20 Million | $ 4.65 Million |
ImmunoCellular Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between ImmunoCellular Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.35 |
| Latest Market Cap to Assets Ratio | 2.25 |
| Asset Growth Rate (YoY) | -4.8% |
| Total Assets | $389.67K |
| Market Capitalization | $877.94K USD |
Valuation Analysis
Premium Asset Valuation: The market values ImmunoCellular Therapeutics Ltd's assets at a significant premium ( 2.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: ImmunoCellular Therapeutics Ltd's assets decreased by 4.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ImmunoCellular Therapeutics Ltd (2005–2024)
The table below shows the annual total assets of ImmunoCellular Therapeutics Ltd from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $389.67K | -4.83% |
| 2023-12-31 | $409.42K | -46.75% |
| 2022-12-31 | $768.80K | -53.86% |
| 2021-12-31 | $1.67 Million | +524.77% |
| 2020-12-31 | $266.70K | -96.19% |
| 2017-12-31 | $7.01 Million | -58.50% |
| 2016-12-31 | $16.89 Million | -43.85% |
| 2015-12-31 | $30.08 Million | +19.48% |
| 2014-12-31 | $25.18 Million | -13.00% |
| 2013-12-31 | $28.94 Million | +7.11% |
| 2012-12-31 | $27.02 Million | +277.85% |
| 2011-12-31 | $7.15 Million | +33.28% |
| 2010-12-31 | $5.37 Million | +264.30% |
| 2009-12-31 | $1.47 Million | -52.92% |
| 2008-12-31 | $3.13 Million | -38.30% |
| 2007-12-31 | $5.07 Million | +373.95% |
| 2006-12-31 | $1.07 Million | -23.54% |
| 2005-12-31 | $1.40 Million | -- |